Analyst Reco. ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Delayed Nasdaq Other stock markets 01:29:51 03/05/2024 am IST			5-day change	1st Jan Change
16.63 ^USD	-1.83%		-1.75%	+11.32%

30/04	ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	CI
18/04	Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	19/04	MT
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	13/03	MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	11/03	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	08/03	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	08/03	MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8	08/12	MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating	14/11	MT
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating	11/23/11	MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating	04/23/04	MT
Cantor Fitzgerald Raises Price Target on ALX Oncology to $23 From $18, Maintains Overweight Rating	04/23/04	MT
Cantor Fitzgerald Cuts Price Target on ALX Oncology Holdings to $18 From $22, Maintains Overweight Rating	14/23/14	MT
HC Wainwright Adjusts ALX Oncology Price Target to $16 From $30, Maintains Buy Rating	11/23/11	MT
UBS Adjusts ALX Oncology's Price Target to $29 From $31, Maintains Buy Rating	15/23/15	MT
Credit Suisse Lowers ALX Oncology Holdings' Price Target to $34 From $38, Keeps Outperform Rating	10/23/10	MT
HC Wainwright Adjusts ALX Oncology Price Target to $30 From $65, Maintains Buy Rating	10/23/10	MT
HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating	09/22/09	MT
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating	26/22/26	MT
Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating	09/22/09	MT
Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating	09/22/09	MT
Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Rating	06/22/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Analyst Reco.

Filters